A cardiac assist apparatus with a controller comprised of a parallel resonant frequency circuit activated by energy input.
Magnetic resonance imaging (MRI) has been developed as an imaging technique adapted to obtain both images of anatomical features of human patients as well as some aspects of the functional activities of biological tissue. These images have medical diagnostic value in determining the state of the health of the tissue examined.
Thus, e.g., as is disclosed in U.S. Pat. No. 6,144,205 (the entire disclosure of which is hereby incorporated by reference into this specification), in an MRI process a patient is typically aligned to place the portion of his anatomy to be examined in the imaging volume of the MRI apparatus. Such MRI apparatus typically comprises a primary magnet for supplying a constant magnetic field (B0) which, by convention, is along the z-axis and is substantially homogeneous over the imaging volume and secondary magnets that can provide linear magnetic field gradients along each of three principal Cartesian axes in space (generally x, y, and z, or x1, x2 and X3, respectively). A magnetic field gradient (ΔBz/Δxi) refers to the variation of the field along the direction parallel to B0 with respect to each of the three principal Cartesian axes, xi. The apparatus also comprises one or more RF (radiofrequency) coils which provide excitation and detection of the NMR signal.
The use of the MRI process with patients who have implanted pacemakers often presents problems. As is known to those skilled in the art, implantable devices (such as implantable pulse generators (IPGs) and cardioverter/defibrillator/pacemakers (CDPs)) are sensitive to a variety of forms of electromagnetic interference (EMI). These devices include sensing and logic systems that respond to low-level signals from the heart. Because the sensing systems and conductive elements of these implantable devices are responsive to changes in local electromagnetic fields, they are vulnerable to external sources of severe electromagnetic noise, and in particular to electromagnetic fields emitted during the magnetic resonance imaging (MRI) procedure. Thus, patients with implantable devices are generally advised not to undergo magnetic resonance imaging (MRI) procedures.
Attempts have been made to protect implantable devices from MRI fields. Thus, for example, U.S. Pat. No. 5,217,010 (to Tsitlik et al.) describes the use of inductive and capacitive filter elements to protect internal circuitry. U.S. Pat. No. 5,968,083 (to Ciciarelli et al.) describes a device adapted to switch between low and high impedance modes of operation in response to EMI insult. U.S. Pat. No. 6,188,926 (to Vock) discloses a control unit for adjusting a cardiac pacing rate of a pacing unit to an interference backup rate when heart activity cannot be sensed due to EMI. The entire disclosure of each of these United States patents is hereby incorporated by reference into this specification.
However, the “solutions” presented by these prior art patents are not entirely adequate. The techniques they describe do not provide a fail-safe system when the protective circuitry or the backup modes of the implantable device fail to protect the implantable device from malfunction due to exposure to electromagnetic fields.
It is an object of this invention to provide a device that will cease furnishing power to a pacemaker at specified intervals while an individual is undergoing an MRI procedure.
It is another object of this invention to provide a means for furnishing power to a pacemaker while protecting it from damage induced by certain radio frequency fields.
In accordance with this invention, there is provided a cardiac assist device comprising means for connecting said cardiac assist device to a heart, means for furnishing electrical impulses from said cardiac assist device to said heart, means for ceasing the furnishing of said electrical impulses to said heart, means for receiving pulsed radio frequency fields, and means for receiving optical signals. The device contains a control circuit comprised of a parallel resonant frequency circuit activated by energy input.
The invention will be described by reference to the following drawings, in which like numerals refer to like elements, and in which:
This specification is presented in two parts. The first part of the specification discusses the utilization of a secondary backup cardiac assist device. The second part of this specification discloses a cardiac assist device comprising means for connecting said cardiac assist device to a heart, means for furnishing electrical impulses from said cardiac assist device to said heart, means for ceasing the furnishing of said electrical impulses to said heart, means for receiving pulsed radio frequency fields, means for receiving optical signals; the device contains a control circuit comprised of a parallel resonant frequency circuit activated by optical input.
A Secondary Backup Cardiac Assist Device
In one embodiment of the present invention, there is provided an implantable device that is resistant to electromagnetic interference comprising first and second modular components and an arrangement for communication between the first module and second modules. During a normal operating mode, the first module performs physiologic functions and the second module is deactivated. When electromagnetic interference is detected, the second module, which is resistant to EMI insult, is activated and the first module is deactivated to further protect its components from EMI.
There is also provided, in another embodiment, an implantable device used to monitor and maintain at least one physiologic function, which is capable of operating in the presence of damaging electromagnetic interference. The implantable device includes primary and secondary modules, each independently protected from EMI damage via at least one shielding and/or filtering, and a non-electrical communication device for communicating in at least one direction between the primary and the secondary modules. The primary module, in response to input from electrical sensing leads, activates the secondary module in a failsafe mode. In the failsafe mode, the secondary module carries out a physiologic function upon activation and in the presence of electromagnetic interference.
In an advantageous embodiment, the physiologic function performed by the implantable device is a cardiac assist function, and the implantable device is a cardiac assist device.
A cross-section diagram of an embodiment of the implantable device according to one embodiment of the present invention is shown in FIG. 1. The body of the device 10 is shown in rectangular form for illustrative purposes only and may have a rounded shape when implanted in the body to avoid tissue damage due to sharp edges. The body of the implantable device 10 includes two modules, a primary module 20 and a secondary module 30, which are hermetically sealed from each other. As will be described further below, according to an embodiment of the present invention, the primary module is a demand pacemaker (DDD) with PCD functionality. As is known in the art, a demand (DDD) pacemaker denotes an implantable device that paces and senses both atrial and ventrical chambers of the heart and can either trigger or inhibit functions depending on detected parameters. During normal operation, the primary module 20 controls the various pacing, cardioversion and defibrillation operations of the implantable device 10 via electrical pacing lead 24, and detects parameters indicating how the heart is functioning via electrical sensing lead 28. Both the pacing leads and sensing leads are bipolar leads; these leads comprise means for connecting the cardiac assist device to a patient's heart (not shown), and they comprise means for furnishing electrical impulses from the cardiac assist device to the heart.
The primary module 20 includes a circuitry portion 21, which contains signal detection and logic circuitry for performing pacing and analysis functions and a battery portion 22. The battery includes either no magnetic material or non-magnetic materials. It may be, for example, a lithium-iodine battery, or its equivalent in another chemistry, e.g. it may have an anode of lithium or carbon and a cathode of iodine, carbon monofluoride, or of silver vanadium oxide, or sulfur dioxide, SOCl2 or SO2 Cl2. The circuitry portion 21 is separated from the battery portion by a non-magnetic and non-corrosive layer 23 which, as described below, can be made from titanium or from a carbon-composite material.
The implantable device 10 also includes a secondary module 30, which contains independent circuitry 31, and battery 32 components also separated by a non-magnetic and non-corrosive layer 33. The secondary module 30 is not activated when the primary module 20 operates, but is only switched on when the primary module malfunctions or detects a voltage induced by electromagnetic interference (EMI) that exceeds a certain level, such as, for example, 3 Volts. During such an occurrence, the secondary module 30 acts as a backup VOO pacemaker (ventricle driven, with no ventricle-sensing input nor any ventricular triggering or inhibition), which is ventricle driven, with no ventricle-sensing input nor any ventricular triggering or inhibition. The secondary module 30 sends pacing signals via a unipolar electrical lead 34 to a ventricle chamber of the heart but does not receive any detected input signals. In accordance with its backup function, the secondary module 30 is supplied with power by a separate battery source 32, which is also of a non-magnetic type, such as a lithium-iodine battery.
Both the primary and secondary modules 20, 30 are encased within shieldings 16 that protect their respective circuitry components from external electromagnetic fields. The shieldings 16 can be made from carbon-matrix composites with continuous carbon fiber filler which is particularly effective in EMI shielding, as discussed in “Electromagnetic interference shielding using continuous carbon-fiber carbon-matrix and polymer-matrix composites,” Luo, X., and Chung, D. D. L., in Composites: Part B (1999), and also suitable for injection molding to encase circuit components. The thickness of the shielding 16 varies from approximately 1 to 3 millimeters. In addition, the batteries of the primary and secondary modules 22, 32 are also encased in separate shieldings 16 made of similar materials.
An optical window 40, made from glass or ceramic, which may be an infrared-transmissive window, is situated between the respective circuitry portions 21 and 31 of the primary and secondary modules 20, 30. The optical window 40 allows for communication to occur between the primary and secondary modules 20, 30. The window 40 is transparent to a range of frequencies of visible or infrared radiation. The thickness of the window has an optimal range of between 0.3 and 1.0 centimeter. To maintain a hermetic seal between the modules 20, 30, the optical window 40 is bound with brazing to sealing fixtures 35, 36 (also referred to as ferrules) that are welded to the respective modules in a manner that may correspond, for example, to that described in, for example, U.S. Pat. No. 5,902,326 to Lessar et al. The entire disclosure of this United States patent is hereby incorporated by reference into this specification.
To further protect the implantable device 10 from external electromagnetic fields, the entire implantable device 10, including the electrical leads 24, 28, 34, is coated with a non-magnetic, biocompatible layer 18 such as rolled titanium or flexible graphite. Flexible graphite has been shown to be a particularly effective shielding gasket material as discussed, for example, in Flexible Graphite for Gasketing, Adsorption, Electromagnetic Interference Shielding, Vibration Damping, Electrochemical Applications, and Stress Sensing, Chung, D. D. L., Journal of Mat. Eng. and Performance, Vol. 92 (2000), due to its resilience, chemical resistance and shielding properties. Graphite/polymer composites may also serve as layer 18. With both the inner 16 and outer 18 shielding layers in place, only the ends of the electrical leads 24, 28, 34, that are in direct contact with heart tissue remain vulnerable to electromagnetic fields. Since the ends of the leads must be exposed in order to pace the heart or detect electrical impulses, electromagnetic interference can propagate through the ends of the leads to the circuitry of the primary and secondary modules 20, 30. The circuitry described below addresses this problem.
The processor 100 is also configured to detect internal errors or circuitry malfunctions. As will be described further, when such errors are detected, the processor 100 initiates a shut down of the primary module 20 and sends a signal via optical window 40 that instructs module 30 to become activated. Furthermore, to preserve the life of the battery 22 for as long as possible, the processor 100 regulates the application of power to various circuit elements in order to reduce static power consumption, in a manner such as described, for example, in U.S. Pat. No. 5,916,237 to Schu; the entire disclosure of this United States patent is hereby incorporated by reference into this specification. The processor 100 is coupled to a memory unit 170 in which instructions and data are stored.
The primary module circuitry 21 also includes an optical source unit 150 coupled to the main bus 125. Optical source unit 150 can be any source of visible or infrared radiation that does not consume significant amounts of power, such as a light emitting diode (LED). During normal operation of the primary module, the optical source 150, according to various implementations known in the art, turns on and off with a specific well-defined frequency or remains continually on. The optical source unit 150 is arranged in relation to the optical window 40 so that radiation emitted from the source unit 150 penetrates through the optical window 40 into the secondary module 30. Both the processor 100 and the optical source unit 150 are situated downstream from a power-down switch 118.
The primary module circuitry 21 also includes an optical sensor unit 160 similarly placed in relation to the optical window 40, in this case, so that it can receive radiation emitted from sources within the secondary module 30. The optical sensor unit 160 preferably is a low-power photodetector sensitive to infrared or visible radiation of a certain wavelength range, preferably from about 400 to 800 nanometers. The optical sensor unit 160 is coupled to the main bus 125 upstream from the power-down switch 118, so that it remains connected to the power supply 22 via the main bus 125 and therefore remains functional, even when the power-down switch 118 is opened.
Similarly, a telemetry unit 180 is also situated upstream from the power-down switch 118 so it also can function when the power-down switch 118 is opened. The telemetry unit 180 may be, for example, a subcutaneous near-infrared signal transmitter, such as described in U.S. Pat. No. 6,192,261 to Gratton et al., that radiates through body tissues and can communicate with a near-by remote programming device equipped with an infrared receiver, for example, during an examination at a medical facility; the entire disclosure of this United States patent is hereby incorporated by reference into this specification. In another implementation, the telemetry unit may use low-power high-frequency radio signals in the Bluetooth® range to communicate with nearby Bluetooth-enabled network devices. In either case, the telemetry unit 180 can communicate information such as the condition of the heart, the remaining life of the implantable device batteries, and whether the primary module 20 is inoperative.
The processor 100 is coupled to pacing lead 24 and sensing lead 28 via respective comparators 110 and 115. The comparator 110 compares voltage on the input lead 28 with a threshold voltage, set to, for example 3 Volts. If the input voltage exceeds the threshold voltage, the comparator 110 sends a signal to the processor 100. The comparator 115 is reverse biased, so that it compares voltages caused by external fields, rather than the output pulse signal on the pacing lead 24, to the threshold voltage, also set to, for example, 3 Volts. If the external voltage appearing on the pacing lead exceeds the threshold voltage, the comparator 115 sends a signal to the processor 100.
When a voltage exceeds the threshold, this indicates that external EMI fields, which may be caused by an MRI device, are present, and that normal operation of the primary module is to cease. To protect the primary module 20, from excessive voltage signals, a switch (not shown) is thrown to redirect lead signal through capacitive and inductive elements 114, which filter signals on the pacing 24 and sensing 28 leads in a way known in the art before they reach the circuitry 21 of the primary module 20. Upon receiving the threshold signal from either comparators 110 or 115, the processor 100 sends a power-down signal to open the switch 118. Additionally, the processor 100 may send a power-down signal to open the switch 118 in response to detection of internal errors or malfunctions. U.S. Pat. No. 5,653,735 describes, for example, one way by which error detection module 104 can detect malfunctions in primary module 20 not caused by EMI; the entire disclosure of this United States patent is hereby incorporated by reference into this specification.
When the power-down switch 118 is opened, the primary module circuitry components downstream from the switch are disconnected from the power supply 22 and no longer operate. In particular, the primary module 20 stops transmitting pacing pulses to the heart and the optical source unit 150 stops radiating through the optical window 40. As noted above, the telemetry unit 180 and the optical sensor unit 160 of the primary module 20 continue operating. When the optical source unit 150 of the primary module 20 stops emitting radiation, this event is detected by the optical detector 260 of the secondary module 30, which is adapted to detect an absence of radiation of either a certain frequency or for a defined period of time, for example, two seconds. Upon detection, the optical detector 260 transmits a power-up signal to switch 218, which closes and connects the secondary module circuitry 31 to the secondary power supply 32. In this manner, the secondary module 30 is activated when the primary module 20 is deactivated.
The secondary module circuitry 31 includes an oscillator stage 230, an amplifier stage 240 and a counter 245.
Because the secondary module 30 only performs basic pacing operations and does not perform diagnostic functions, if the primary module 20 shuts down in response to temporary electromagnetic interference, it is important to reactivate the primary module 20 (and deactivate the secondary module 30) when the implantable device 10 is no longer threatened by the electromagnetic interference. For example, since MRI procedures generally last approximately half an hour, the primary module 20 should only be deactivated for a half an hour plus an additional amount as a tolerance factor, for example.
To keep track of the length of time the secondary module 30 is operating, the secondary module circuitry 31 includes a counter element 245 coupled to the oscillator element 230, that counts oscillator transitions. Once the secondary module is turned on, the counter element 245 increments and can trigger a reset function to turn the primary module 20 back on when it reaches a specific count after a pre-defined length of time.
In one embodiment, the counter 245 triggers an optical source 250 to transmit radiation through the optical window 40 to the primary module 20 in which the radiation is detected by optical sensor unit 160. For example, this radiation may be a single pulse lasting for one second. In response to detection of radiation, the optical sensor unit 160 sends a trigger signal to close the power-down switch 118 and turn the primary module 20 back on. When the processor 100 of the primary module 20 detects that it is connected to the power supply 22, it runs diagnostic tests in a power-on-reset (POR) mode, such as described, for example, in U.S. Pat. No. 6,016,448 to Busacker et al., wherein initial conditions of the heart are determined and stored in memory unit 170; the entire disclosure of this patent is hereby incorporated by reference into this specification. During this mode, the processor 100 also runs internal error checks, so that if the original power-down was caused by internal malfunction, and the cause of the malfunction has not been corrected, the secondary module is not deactivated.
If the internal error checks indicate that the primary module circuitry 21 can support the PCD cardiac assist functions properly, the processor 100 sends a trigger to the pacing unit 140 to begin operation and simultaneously sends a transmission signal to the optical source unit 150, whereupon the optical source unit 150 turns on or begins to pulse according to its pre-set frequency. The optical detector 260 of the secondary unit then detects that the optical source unit 150 of the primary unit is on, and in response, triggers the switch 218 to open, deactivating the secondary module circuitry 31.
To further improve the EMI resistance of the secondary module 30, the circuitry components 31 may be arranged, according to one embodiment of the secondary module circuitry 31, in a “cordwood” design such as is shown in FIG. 4. As illustrated, in this arrangement all components are laid side by side on a teflon block 415, to avoid adherence, and a thin layer of mixed epoxy is laid onto the circuit components, which are aligned so as to minimize the wiring between the various components which reduces extraneous induced EMI pickup. When the epoxy has cured, the circuit 410 is removed from the teflon block and the components are wired as illustrated in FIG. 4. The resistor and capacitor components 425 are shown hand-wired with very short leads, which reduces electrical pickup signals from an MRI in progress that might disturb the operation of the pacemaker circuitry.
In another embodiment, the secondary module circuitry 31 comprises a custom designed integrated circuit (IC) fabricated, with the active semiconductors, resistors, capacitors and the connecting wires part of the IC. A monolithic IC of this type is described, for example, in U.S. Pat. No. 5,649,956 965 to Pons et al. The entire disclosure of this patent is hereby incorporated by reference into this specification.
Another Embodiment of the Invention Utilizing a Parallel Resonant Circuit
MRI has been developed as an imaging modality used to obtain images of anatomical features of human patients as well as some aspects of the functional activity of biological tissue. The images have medical diagnostic value in determining the state of health of the tissue examined. To obtain images, typically, the patient is aligned to place the portion of the anatomy to be examined in the imaging volume of a MRI apparatus. The apparatus typically comprises a primary magnet for supplying a constant magnetic field (B0) which by convention is along the z-axis and is substantially homogeneous over the imaging volume and secondary magnets that can provide linear magnetic field gradients along each of three principal Cartesian axes in space (generally x, y, and z, or x1, x2 and x3, respectively). A magnetic field gradient (ΔBz/Δxi) refers to the variation of the field along the direction parallel to B0 with respect to each of the three principal Cartesian axes, xi. The apparatus also comprises one or more RF (radio frequency) coils which provide excitation and detection of the NMR signal.
As is known to those skilled in the art of MRI scanner design, there is a requirement to isolate the RF receive coil from the RF transmit coil. One method to accomplish this is the utilization of a parallel resonant circuit tuned to the Larmor frequency of the MRI system. The Larmor frequency of the MRI system is dependent upon the static magnetic field magnitude. The majority of clinical scanners in use today use a 1.5 Tesla superconducting magnet. There are a variety of static magnetic field magnitudes, which are used in research environments and in the future may be utilized clinically. Through the Larmor relationship it is known that
ω=γB0
where ω is in radians per second (=2π times the frequency), γ is the gyromagnetic ratio (approximately 42.6 megahertz [MHz] per Tesla for hydrogen) and B0 is the static magnetic field magnitude. The resonant frequency at 1.5 Tesla for hydrogen in clinical scanners is approximately 63.9 megahertz. Therefore, in the range of 0.5 to 14.1 Tesla, the resonant frequency range will be 21.3 megahertz to 651 megahertz. Clinical MRI almost exclusively images utilizing the resonance of hydrogen, therefore the value for γ of 42.6 megahertz per Tesla is standard.
One preferred process of the instant invention is presented in FIG. 5. Referring to
One may use timing circuits known to those skilled in the art as MRI timing circuitry 441. Thus, e.g., referring to FIG. 8 of U.S. Pat. No. 4,379,262 (“Nuclear magnetic resonance systems”), there is disclosed a detailed timing and control arrangement 14. The control block shown at element 25 of such
Timing circuits of the type disclosed in U.S. Pat. No. 4,379,262 are well known and are adapted to control any sequence of operations which is known in advance. These circuits can readily be adapted to a chosen examination procedure.
Referring again to U.S. Pat. No. 4,379,262, and to
By way of further illustration, suitable MRI instrumentation timing circuitry is disclosed in U.S. Pat. No. 4,333,053 (“Imaging systems”), the entire disclosure of which is hereby incorporated by reference into this specification. Referring to U.S. Pat. No. 4,333,053, and to
Referring again to U.S. Pat. No. 4,333,053, The NMR apparatus 40 is first caused to operate with a GR gradient in the manner previously disclosed, and the resonance signals thus provided are demodulated in demodulators 43 and 44 at frequency f0 from a reference oscillator 45. To preserve phase information, demodulation is into in-phase and quadrature components, the reference for demodulator 44 being shifted by 90° in circuits 46.
Referring again to
As is known to those skilled in the art, parallel-resonant circuits have very high impedances at or near the resonant frequency of the circuit and essentially perform as open switches at such resonant frequencies. When the parallel resonant circuit becomes functional (see step 448), it then prevents current at or near the resonant frequency from passing through it. Thus, when this parallel-resonant circuit is interconnected between a cardiac assist device circuit and cardiac leads and is functional, it will effectively open the circuitry of the cardiac assist device, totally inhibiting current induced by the radio frequency fields of the MRI system from flowing to the device or via the leads to the heart (see step 450). Therefore, the functional resonant circuit prevents the occurrence of deleterious effects on the cardiac assist device and the heating of the electrodes placed in the cardiac tissue. Thus, in the device of this application, the parallel resonant circuit which is activated provides means for ceasing the furnishing of electrical impulses from a cardiac assist device to a patient's heart; when alternating currents are supplied which deviate from frequency at which resonance occurs in the parallel resonant circuit, current is allowed to flow to the device, the amount of flow depending upon the deviation from the resonant frequency. Consequently, when the parallel circuit is not activated (at frequencies more or less than the resonant frequency), it acts as a closed switch, and there is provided means for furnishing the electrical impulses to the heart.
As will be apparent to those skilled in the art, the amount of current which will be allowed to flow at frequencies other than the resonant frequency may be adjusted by adjusting the “Q” of the circuit which, in turn, depends upon, e.g., the resistance in the circuit.
When the timing circuitry signals the MRI gradient field pulses and the trigger voltage off, the circuitry of the cardiac assist device is activated because the parallel-resonant circuit ceases to exist. However, since, in this event, the pulsed radio frequency is no longer being produced, there is no danger to the pacemaker circuit and the patient within whom such circuit is disposed.
Referring to
A simplified depiction of the timing relationship between the RF coil activation, the triggering of the optical emitter (OE) and the output of the cardiac assist device is shown in
Referring again to
Once the radio frequency coils of the MRI scanner are activated, radio frequency fields are generated whose concentration is at a maximum within the core of the coils. These fields interact with and are “received by” all materials with which it contacted. A cardiac assist device within a patient will be contacted and affected by such R.F. fields. The R.F. fields may trigger the cardiac assist device and cause rapid pacing when, in fact, such is not required by the patient. Alternatively, or additionally, the R.F. fields often induce a voltage within the cardiac assist device which is so substantial that it often destroys the device.
As used in the specification, the term “receiving pulsed radio frequency fields” includes any device which is in any manner affected by the pulsed radio frequency fields. Thus, even though the cardiac assist device might not contain a formal antenna for receiving the pulsed radio frequency fields, it still contains means for receiving such pulsed radio frequency fields in that one or more of its components interact with such fields. Without wishing to be bound to any particular theory, applicants believe that the leads of the cardiac assist device often act as antennae.
A multitude of waveforms may be applied for the MRI sequence. There are also a variety of cardiac assist devices (CADs) providing different pulsing and sensing capabilities. The timing description shown in
By way of illustration and not limitation, an example of one complex scenario for the sensing and pacing steps is described in U.S. Pat. No. 4,800,883 (“Apparatus for generating multiphasic defibrillation pulse waveform”), the entire disclosure of which is hereby incorporated by reference into this specification.
By way of further illustration, U.S. Pat. No. 6,163,724 (“Microprocessor capture detection circuit and method”) discloses means for auto-capture detection in a variety of pacing and sensing modes. Thus, e.g., this patent discloses a software programmable (device means such as a microprocessor) that discriminates between evoked response signals and post-pace polarization signals sensed by an implantable medical device. The polarity of the positive or negative change in voltage in respect of time (or dv/dt) of the waveform incident on the lead electrodes is monitored during a short period of time immediately following a paced event. The patent also discloses that the post-pace polarization signal exhibits a relatively constant polarity during the capture detect window, that the evoked response signal may cause the polarity of post-pace polarization signal to reverse during the capture detect window, that the sign of the post-pace polarization polarity, either positive or negative, is determined by the design of the specific output circuitry. In the device of this patent, the evoked response signal may reverse the polarity of the sensed signal in either case, from positive to negative or from negative to positive, during the time window of interest. In another embodiment of the patent, and when the magnitude of the post-pace polarization is so great that the evoked response does not reverse the polarity of the waveform, discrimination of the evoked response is achieved by noting an acceleration (or increasing magnitude of dv/dt) in the sensed signal or waveform. The entire disclosure of this United States patent is hereby incorporated by reference into this specification.
By way of further illustration, U.S. Pat. No. 6,169,921 (“Autocapture determination for an implantable cardioverter defibrillator”) discloses a cardiac pacing/defibrillation system that enhances the ability of a cardiac pacer to automatically detect whether a pacing stimulus results in heart capture or contraction. The cardiac pacing/defibrillation system of this patent includes a pacing circuit that attenuates polarization voltages or “afterpotential” which develop at the heart tissue/electrode interface following the delivery of a stimulus to the heart tissue, which thereby allows the pacing electrodes to be utilized to sense an evoked response to the pacing stimulus. The cardiac pacing/defibrillation system of this patent may utilize the ventricular coil electrode and superior vena cava coil electrode to sense an evoked response, thereby eliminating the necessity for an additional ventricular lead for sensing an evoked response. The device of this patent allows accurate detection of an evoked response of the heart, to thereby determine whether each pacing stimulus results in capture. The entire disclosure of this United States patent is hereby incorporated by reference into this specification.
In step 446 of
Referring again to
where the units of f are in hertz, L are in henries, and C are in farads.
In one embodiment, by the use of a variable resistor (not shown), the “Q” (quality factor) of the parallel resonsant may be varied, thus varying the amount of current which is allowed to flow at specified frequencies off of the resonant frequency.
The circuits depicted in
The Figures of U.S. Pat. No. 6,144,205 disclose resonant circuits having a first inductance and being tuned to resonate at a Larmor frequency.
A dc trigger voltage (see step 444 of
In one preferred embodiment, the direct current 511 applied to PIN diode 508 is applied from an external source via an electrical lead, such a lead from a trigger device adapted to produce such current when initiated by a dc trigger voltage from a separate source, such as the timing circuitry in an MRI scanner. When the direct current 511 is not applied to the PIN diode 510, the circuit is open (disabled).
In one preferred embodiment, the diodes 534, 542, 544, 574, and 576 in
Referring again to
The device of this invention is comprised of means for receiving an energy input and, in response thereto, for activating the parallel resonant circuit described above. One form of energy which will activate the parallel resonant is photonic energy, and a switching device incorporating such photonic energy will be described in the remainder of this specification. Alternatively, or additionally, one may use other forms of energy to activate the parallel resonant circuit. Thus, for example, one may utilize a direct current voltage supplied by the MRI scanner and/or another apparatus to activate, e.g., a diode (such as, e.g., a pin diode).
Referring to both
In one embodiment, optical radiation is transmitted through the skin a patient. In one aspect of this embodiment, one may use near infrared light in the range of from about 700 to about 900 nanometers and, preferably, from about 750 to about 850 nanometers. It is often preferred to use optical radiation of from about 775 to about 825 nanometers; it is known that radiation of about 800 nanometers efficiently is transmitted through the skin of human beings.
As will be apparent, a photodector may be disposed beneath the skin, substantially anywhere in the living organism. It is preferred not to have to transmit the light through highly absorbent body tissue, such as a liver, or through bone. However, subcutaneous placement of the photodetector(s) beneath one or more skin layers is relatively efficient.
Referring again to
In one embodiment, the device depicted in FIG. 5 of U.S. Pat. No. 6,144,205 may be utilized in the apparatus of this invention. Referring to such
As a variation of the aforementioned embodiment, and referring again to U.S. Pat. No. 6,144,205, the semiconductor switch 188 may also be a photodiode or other type of photosensitive device. In this case, best operation will be obtained if provision is made to adequately illuminate both photosensitive devices 190 and 188 in order to render those devices conductive.
FIG. 6 of U.S. Pat. No. 6,144,205 illustrates an alternative third embodiment 354 of the optical technique for disabling an RF antenna. This embodiment has a parallel resonant blocking loop 201, comprised of photosensitive semiconductor switch 214, inductor 212, and capacitance 204 rather than capacitance 206 corresponding to capacitances 174 and 198 in
As a variation of the third embodiment of this patent, the modifications of the second embodiment of the patent shown in
In another embodiment, a circuit as shown in
Thus, e.g., one may use the device depicted in U.S. Pat. No. 6,031,710, the entire disclosure of which is hereby incorporated by reference into this specification. This patent discloses a capacitive filter feedthrough assembly and method of making the same for shielding an implantable medical device, such as a pacemaker or a defibrillator, from electromagnetic interference or noise. A ferrule is adapted for mounting onto a conductive device housing by welding, soldering, brazing or gluing, and supports a terminal pin for feedthrough passage to a housing interior. A capacitive filter is mounted at the inboard side of a device housing, with capacitive filter electrode plate sets coupled respectively to the housing and the terminal pin by an electrically conductive combination of adhesive, brazing and soldering. In one embodiment of the invention of this patent, multiple capacitive filters are provided in an array within a common base structure, where each capacitive filter is associated with a respective terminal pin.
Referring again to
Referring again to FIG. 1 and
Referring to
The use of the resonant circuits of
In another separate embodiment the secondary module will be omitted and the remote signaling derived from the scanner will influence only a resonant circuit switch from values for the capacitor and inductors within this type of circuit are required such that a high Q value of resonance is acquired within the circuit.
The foregoing description was primarily directed to a preferred embodiment of the invention. Although some attention was given to various alternatives within the scope of the invention, it is anticipated that one skilled in the art will likely realize additional alternatives that are now apparent from disclosure of embodiments of the invention. For example, the invention may be used to disable a transmit antenna rather than a receive antenna, and may be used in systems other than MRI systems where similar functionality is desirable. Accordingly, the scope of the invention should be determined from the following claims and not limited by the above disclosure.
This application is a continuation-in-part of applicants' copending patent application U.S. Ser. No. 09/839,286, filed on Apr. 20, 2001. Priority for the U.S. Ser. No. 09/839,286 case was based upon provisional patent application U.S. Ser. No. 60/198,631, filed on Apr. 20, 2000.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3057356 | Greatbatch | Oct 1962 | A |
| 3478746 | Greatbatch | Nov 1969 | A |
| 3508167 | Russell, Jr. | Apr 1970 | A |
| 3669095 | Kobayshi et al. | Jun 1972 | A |
| 3686958 | Porter et al. | Aug 1972 | A |
| 3718142 | Mulier | Feb 1973 | A |
| 3789667 | Porter et al. | Feb 1974 | A |
| 3825015 | Berkovits | Jul 1974 | A |
| 4012641 | Brickerd, Jr. et al. | Mar 1977 | A |
| 4041954 | Ohara | Aug 1977 | A |
| 4050004 | Greatbatch | Sep 1977 | A |
| 4071032 | Schulman | Jan 1978 | A |
| 4091818 | Brownlee et al. | May 1978 | A |
| 4200110 | Peterson et al. | Apr 1980 | A |
| 4210029 | Porter | Jul 1980 | A |
| 4254776 | Tanie et al. | Mar 1981 | A |
| 4325382 | Miodownik | Apr 1982 | A |
| 4333053 | Harrison et al. | Jun 1982 | A |
| 4341221 | Testerman | Jul 1982 | A |
| 4379262 | Young | Apr 1983 | A |
| 4432363 | Kakegawa | Feb 1984 | A |
| 4450408 | Tiemann | May 1984 | A |
| 4476870 | Peterson et al. | Oct 1984 | A |
| 4491768 | Slicker | Jan 1985 | A |
| 4545381 | Bournay, Jr. et al. | Oct 1985 | A |
| 4611127 | Ibrahim et al. | Sep 1986 | A |
| 4677471 | Takamura et al. | Jun 1987 | A |
| 4686964 | Yunoki et al. | Aug 1987 | A |
| 4691164 | Haragashira | Sep 1987 | A |
| 4719159 | Clark et al. | Jan 1988 | A |
| 4727874 | Bowers et al. | Mar 1988 | A |
| 4763075 | Weigert | Aug 1988 | A |
| 4784461 | Abe et al. | Nov 1988 | A |
| 4798443 | Knipe et al. | Jan 1989 | A |
| 4800883 | Winstrom | Jan 1989 | A |
| 4804244 | Hasegawa et al. | Feb 1989 | A |
| 4827906 | Robicsek et al. | May 1989 | A |
| 4827934 | Ekwall | May 1989 | A |
| 4858610 | Callaghan et al. | Aug 1989 | A |
| 4879992 | Nishigaki et al. | Nov 1989 | A |
| 4880004 | Baker, Jr. et al. | Nov 1989 | A |
| 4903701 | Moore et al. | Feb 1990 | A |
| 4911525 | Hicks et al. | Mar 1990 | A |
| 4930521 | Metzger et al. | Jun 1990 | A |
| 4934785 | Mathis et al. | Jun 1990 | A |
| 4987897 | Funke | Jan 1991 | A |
| 4991590 | Shi | Feb 1991 | A |
| 5010888 | Jadvar et al. | Apr 1991 | A |
| 5055810 | deLaChapelle et al. | Oct 1991 | A |
| 5058586 | Heinze | Oct 1991 | A |
| 5061680 | Paulson et al. | Oct 1991 | A |
| 5089697 | Prohaska | Feb 1992 | A |
| 5113859 | Funke | May 1992 | A |
| 5131409 | Lobarev et al. | Jul 1992 | A |
| 5154387 | Trailer | Oct 1992 | A |
| 5158932 | Hinshaw et al. | Oct 1992 | A |
| 5168871 | Grevious | Dec 1992 | A |
| 5178149 | Imburgia et al. | Jan 1993 | A |
| 5214730 | Nagasawa et al. | May 1993 | A |
| 5217009 | Kronberg | Jun 1993 | A |
| 5217010 | Tsitlik et al. | Jun 1993 | A |
| 5226210 | Koskenmaki et al. | Jul 1993 | A |
| 5240004 | Walinsky et al. | Aug 1993 | A |
| 5243979 | Stein et al. | Sep 1993 | A |
| 5265602 | Anderson et al. | Nov 1993 | A |
| 5267564 | Barcel et al. | Dec 1993 | A |
| 5279292 | Baumann et al. | Jan 1994 | A |
| 5324310 | Greeninger et al. | Jun 1994 | A |
| 5330512 | Hauck et al. | Jul 1994 | A |
| 5348010 | Schnall et al. | Sep 1994 | A |
| 5354220 | Ganguly et al. | Oct 1994 | A |
| 5370668 | Shelton | Dec 1994 | A |
| 5387229 | Poore | Feb 1995 | A |
| 5387232 | Trailer | Feb 1995 | A |
| 5402070 | Shelton et al. | Mar 1995 | A |
| 5410413 | Sela | Apr 1995 | A |
| 5415653 | Wardle et al. | May 1995 | A |
| 5425373 | Causey, III | Jun 1995 | A |
| 5435308 | Gallup et al. | Jul 1995 | A |
| 5435316 | Kruse | Jul 1995 | A |
| 5438987 | Thacker et al. | Aug 1995 | A |
| 5445151 | Darrow et al. | Aug 1995 | A |
| 5453838 | Danielian et al. | Sep 1995 | A |
| 5454837 | Lindegren et al. | Oct 1995 | A |
| 5456698 | Byland et al. | Oct 1995 | A |
| 5464014 | Sugahara | Nov 1995 | A |
| 5476095 | Schnall et al. | Dec 1995 | A |
| 5520190 | Benedict et al. | May 1996 | A |
| 5523534 | Meister et al. | Jun 1996 | A |
| 5569158 | Suzuki et al. | Oct 1996 | A |
| 5570671 | Hickey | Nov 1996 | A |
| 5574811 | Bricheno et al. | Nov 1996 | A |
| 5575772 | Lennox | Nov 1996 | A |
| 5582170 | Soller | Dec 1996 | A |
| 5590227 | Osaka et al. | Dec 1996 | A |
| 5601611 | Fayram et al. | Feb 1997 | A |
| 5603697 | Grundy et al. | Feb 1997 | A |
| 5604433 | Theus et al. | Feb 1997 | A |
| 5611016 | Fangmann et al. | Mar 1997 | A |
| 5619605 | Ueda et al. | Apr 1997 | A |
| 5626618 | Ward et al. | May 1997 | A |
| 5626619 | Jacobson et al. | May 1997 | A |
| 5631988 | Swirhun et al. | May 1997 | A |
| 5634720 | Gallup et al. | Jun 1997 | A |
| 5649965 | Pons et al. | Jul 1997 | A |
| 5653735 | Chen et al. | Aug 1997 | A |
| 5654317 | Fujioka et al. | Aug 1997 | A |
| 5658966 | Tsukamoto et al. | Aug 1997 | A |
| 5679026 | Fain et al. | Oct 1997 | A |
| 5683435 | Truex et al. | Nov 1997 | A |
| 5697958 | Paul et al. | Dec 1997 | A |
| 5699801 | Atalar et al. | Dec 1997 | A |
| 5709225 | Budgifvars et al. | Jan 1998 | A |
| 5716386 | Ward et al. | Feb 1998 | A |
| 5723856 | Yao et al. | Mar 1998 | A |
| 5733247 | Fallon | Mar 1998 | A |
| 5738105 | Kroll | Apr 1998 | A |
| 5749910 | Brumwell et al. | May 1998 | A |
| 5752977 | Grevious et al. | May 1998 | A |
| 5755739 | Sun et al. | May 1998 | A |
| 5755742 | Schuelke et al. | May 1998 | A |
| 5759197 | Sawchuk et al. | Jun 1998 | A |
| 5761354 | Kuwano et al. | Jun 1998 | A |
| 5766227 | Nappholz et al. | Jun 1998 | A |
| 5772604 | Langberg et al. | Jun 1998 | A |
| 5774501 | Halpern et al. | Jun 1998 | A |
| 5776167 | Levine et al. | Jul 1998 | A |
| 5776168 | Gunderson | Jul 1998 | A |
| 5782241 | Felblinger et al. | Jul 1998 | A |
| 5782880 | Lahtinen et al. | Jul 1998 | A |
| 5808730 | Danielian et al. | Sep 1998 | A |
| 5814087 | Renirie | Sep 1998 | A |
| 5814089 | Stokes et al. | Sep 1998 | A |
| 5814090 | Latterell et al. | Sep 1998 | A |
| 5814091 | Dahlberg et al. | Sep 1998 | A |
| 5817130 | Cox et al. | Oct 1998 | A |
| 5817133 | Houben | Oct 1998 | A |
| 5817136 | Nappholz et al. | Oct 1998 | A |
| 5818990 | Steijer et al. | Oct 1998 | A |
| 5827195 | Lander | Oct 1998 | A |
| 5827997 | Chung et al. | Oct 1998 | A |
| 5830209 | Savage et al. | Nov 1998 | A |
| 5836895 | Ramsey, III | Nov 1998 | A |
| 5861012 | Stroebel | Jan 1999 | A |
| 5865839 | Doorish | Feb 1999 | A |
| 5867361 | Wolf et al. | Feb 1999 | A |
| 5868664 | Speier et al. | Feb 1999 | A |
| 5869412 | Yenni, Jr. et al. | Feb 1999 | A |
| 5870272 | Seifried et al. | Feb 1999 | A |
| 5871509 | Noren | Feb 1999 | A |
| 5871512 | Hemming et al. | Feb 1999 | A |
| 5873898 | Hemming et al. | Feb 1999 | A |
| 5882108 | Fraizer | Mar 1999 | A |
| 5882305 | Dumoulin et al. | Mar 1999 | A |
| 5891171 | Wickham | Apr 1999 | A |
| 5895980 | Thompson | Apr 1999 | A |
| 5897577 | Cinbis et al. | Apr 1999 | A |
| 5899927 | Ecker et al. | May 1999 | A |
| 5902326 | Lessar et al. | May 1999 | A |
| 5916162 | Snelton et al. | Jun 1999 | A |
| 5916237 | Schu | Jun 1999 | A |
| 5917625 | Ogusu et al. | Jun 1999 | A |
| 5919135 | Lemelson | Jul 1999 | A |
| 5928145 | Ocali et al. | Jul 1999 | A |
| 5928270 | Ramsey, III | Jul 1999 | A |
| 5928570 | Reo | Jul 1999 | A |
| 5940554 | Chang et al. | Aug 1999 | A |
| 5946086 | Bruce | Aug 1999 | A |
| 5951596 | Bellinger | Sep 1999 | A |
| 5954660 | Legay et al. | Sep 1999 | A |
| 5957857 | Hartley | Sep 1999 | A |
| 5963034 | Mahapatra et al. | Oct 1999 | A |
| 5963690 | Cheng | Oct 1999 | A |
| 5967977 | Mullis et al. | Oct 1999 | A |
| 5968083 | Ciciarelli et al. | Oct 1999 | A |
| 5973779 | Ansari et al. | Oct 1999 | A |
| 5973906 | Stevenson et al. | Oct 1999 | A |
| 5978710 | Prutchi et al. | Nov 1999 | A |
| 5982961 | Pan et al. | Nov 1999 | A |
| 5985129 | Gough et al. | Nov 1999 | A |
| 5987995 | Sawatari et al. | Nov 1999 | A |
| 5999853 | Stoop et al. | Dec 1999 | A |
| 5999857 | Weijand et al. | Dec 1999 | A |
| 6005191 | Tzeng et al. | Dec 1999 | A |
| 6011994 | Kronberg | Jan 2000 | A |
| 6013376 | Yenni, Jr. | Jan 2000 | A |
| 6016448 | Busacker et al. | Jan 2000 | A |
| 6016477 | Ehnebuske et al. | Jan 2000 | A |
| 6023641 | Thompson | Feb 2000 | A |
| 6024738 | Daikuzono et al. | Feb 2000 | A |
| 6026316 | Kucharczyk | Feb 2000 | A |
| 6029086 | Kim et al. | Feb 2000 | A |
| 6029087 | Wohlgemuth | Feb 2000 | A |
| 6031710 | Wolf et al. | Feb 2000 | A |
| 6036639 | Allred, III et al. | Mar 2000 | A |
| 6036654 | Quinn et al. | Mar 2000 | A |
| 6044301 | Hartlaub et al. | Mar 2000 | A |
| 6052613 | Takaki | Apr 2000 | A |
| 6052614 | Morris, Sr. et al. | Apr 2000 | A |
| 6052623 | Fenner et al. | Apr 2000 | A |
| 6055455 | O'Phelan et al. | Apr 2000 | A |
| 6056415 | Allred, III et al. | May 2000 | A |
| 6056721 | Shulze | May 2000 | A |
| 6064906 | Langberg et al. | May 2000 | A |
| 6066096 | Smith et al. | May 2000 | A |
| 6067472 | Vonk et al. | May 2000 | A |
| 6076003 | Rogel | Jun 2000 | A |
| 6080829 | Tapsak et al. | Jun 2000 | A |
| 6090473 | Yoshikawa et al. | Jul 2000 | A |
| 6090728 | Yenni, Jr. et al. | Jul 2000 | A |
| 6091015 | delValle et al. | Jul 2000 | A |
| 6091744 | Sorin et al. | Jul 2000 | A |
| 6091987 | Thompson | Jul 2000 | A |
| 6101973 | Stewart et al. | Aug 2000 | A |
| 6118910 | Chang | Sep 2000 | A |
| 6119031 | Crowley | Sep 2000 | A |
| 6129745 | Sun et al. | Oct 2000 | A |
| 6134003 | Tearney et al. | Oct 2000 | A |
| 6134478 | Spehr | Oct 2000 | A |
| 6142678 | Cheng | Nov 2000 | A |
| 6144205 | Souza et al. | Nov 2000 | A |
| 6144866 | Miesel et al. | Nov 2000 | A |
| 6144881 | Hemming et al. | Nov 2000 | A |
| 6146415 | Fitz | Nov 2000 | A |
| 6148222 | Ramsey, III | Nov 2000 | A |
| 6148229 | Morris, Sr. et al. | Nov 2000 | A |
| 6149313 | Giebel et al. | Nov 2000 | A |
| 6163724 | Hemming et al. | Dec 2000 | A |
| 6166806 | Tjin | Dec 2000 | A |
| 6169921 | Ken Knight et al. | Jan 2001 | B1 |
| 6171240 | Young et al. | Jan 2001 | B1 |
| 6173203 | Barkley et al. | Jan 2001 | B1 |
| 6179482 | Takizawa et al. | Jan 2001 | B1 |
| 6188926 | Vock | Feb 2001 | B1 |
| 6192261 | Gratton et al. | Feb 2001 | B1 |
| 6198968 | Prutchi et al. | Mar 2001 | B1 |
| 6198972 | Hartlaub et al. | Mar 2001 | B1 |
| 6208899 | Kroll | Mar 2001 | B1 |
| 6216041 | Tierney et al. | Apr 2001 | B1 |
| 6223083 | Rosar | Apr 2001 | B1 |
| 6226545 | Gilderdale | May 2001 | B1 |
| 6230060 | Mawhinney | May 2001 | B1 |
| 6236879 | Konings | May 2001 | B1 |
| 6238686 | Burrell et al. | May 2001 | B1 |
| 6240317 | Villaseca et al. | May 2001 | B1 |
| 6245020 | Moore et al. | Jun 2001 | B1 |
| 6246910 | Bonnet et al. | Jun 2001 | B1 |
| 6247474 | Greeninger et al. | Jun 2001 | B1 |
| 6254632 | Wu et al. | Jul 2001 | B1 |
| 6256537 | Stoop et al. | Jul 2001 | B1 |
| 6256541 | Heil et al. | Jul 2001 | B1 |
| 6258087 | Edwards et al. | Jul 2001 | B1 |
| 6259843 | Kondo | Jul 2001 | B1 |
| 6259954 | Conger et al. | Jul 2001 | B1 |
| 6263229 | Atalar et al. | Jul 2001 | B1 |
| 6263242 | Mika et al. | Jul 2001 | B1 |
| 6266555 | Werner et al. | Jul 2001 | B1 |
| 6266563 | Ken Knight et al. | Jul 2001 | B1 |
| 6266564 | Hill et al. | Jul 2001 | B1 |
| 6266566 | Nichols et al. | Jul 2001 | B1 |
| 6270457 | Bardy | Aug 2001 | B1 |
| 6270831 | Kumar et al. | Aug 2001 | B2 |
| 6272377 | Sweeney et al. | Aug 2001 | B1 |
| 6272380 | Warman et al. | Aug 2001 | B1 |
| 6274265 | Kraska et al. | Aug 2001 | B1 |
| 6275730 | Ken Knight et al. | Aug 2001 | B1 |
| 6275732 | Hsu et al. | Aug 2001 | B1 |
| 6275734 | McClure et al. | Aug 2001 | B1 |
| 6277078 | Porat et al. | Aug 2001 | B1 |
| 6277107 | Lurie et al. | Aug 2001 | B1 |
| 6278057 | Avellanet | Aug 2001 | B1 |
| 6278277 | Zeiger | Aug 2001 | B1 |
| 6278894 | Salo et al. | Aug 2001 | B1 |
| 6278897 | Rutten et al. | Aug 2001 | B1 |
| 6296654 | Ward | Oct 2001 | B1 |
| 6317633 | Jorgenson et al. | Nov 2001 | B1 |
| 6367984 | Stephenson et al. | Apr 2002 | B1 |
| Number | Date | Country |
|---|---|---|
| WO 0174241 | Oct 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030036776 A1 | Feb 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60198631 | Apr 2000 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09839286 | Apr 2001 | US |
| Child | 09921066 | US |